Neurobloc (Solstice Neurosciences)
- Neurobloc (Solstice Neurosciences) – general information
- Pharmacology of Neurobloc (Solstice Neurosciences)
- Neurobloc (Solstice Neurosciences) for patients
- Neurobloc (Solstice Neurosciences) interactions
- Neurobloc (Solstice Neurosciences) contraindications
- Additional information about Neurobloc (Solstice Neurosciences)
Neurobloc (Solstice Neurosciences) - General Information
Neurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps.
Pharmacology of Neurobloc (Solstice Neurosciences)
Neurobloc (Solstice Neurosciences) inhibits acetylcholine release at the neuromuscular junction via a three stage process: 1) Heavy Chain mediated neurospecific binding of the toxin, 2) internalization of the toxin by receptor-mediated endocytosis, and 3) ATP and pH dependent translocation of the Light Chain to the neuronal cytosol where it acts as a zinc-dependent endoprotease cleaving polypeptides essential for neurotransmitter release.
Neurobloc (Solstice Neurosciences) for patients
Neurobloc (Solstice Neurosciences) Interactions
Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
The effect of administering different botulinum neurotoxin serotypes at the same time or within less than 4 months of each other is unknown. However, neuromuscular paralysis may be potentiated by co-administration or overlapping administration of different botulinum toxin serotypes.
Neurobloc (Solstice Neurosciences) Contraindications
MYOBLOC is contraindicated in patients with a known hypersensitivity to any ingredient in the formulation.
Additional information about Neurobloc (Solstice Neurosciences)
Neurobloc (Solstice Neurosciences) Indication: For the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.
Mechanism Of Action: Neurobloc (Solstice Neurosciences) binds to and cleaves the synaptic Vesicle Associated Membrane Protein (VAMP, also known as synaptobrevin) which is a component of the protein complex responsible for docking and fusion of the synaptic vesicle to the presynaptic membrane, a necessary step to neurotransmitter release.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Botulinum Toxin Type B
Synonyms: BTX-B; Botulinum neurotoxin type B precursor
Drug Category: Antidystonic Agents
Drug Type: Biotech; Approved
Other Brand Names containing Botulinum Toxin Type B: Myobloc (Solstice Neurosciences); Neurobloc (Solstice Neurosciences);
Absorption: Though pharmacokinetic or ADME studies were not performed, Botulinum Toxin Type B is not expected to be present in the peripheral blood at measurable levels following IM injection at the recommended doses.
Toxicity (Overdose): One unit of Botulinum Toxin Type B corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice.
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: Not Available
Dosage Forms of Neurobloc (Solstice Neurosciences): Injection, solution Intramuscular
Chemical IUPAC Name: Not Available
Chemical Formula: C6760H10447N1743O2010S32
Botulinum Toxin Type B on Wikipedia: https://en.wikipedia.org/wiki/Botulinum_toxin
Organisms Affected: Humans and other mammals